Clinical Trial

Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases

Withdrawn
View on ClinicalTrials.gov →
Why the trial stopped
Due to corporate strategic adjustment.
Summary
This study is a single-arm, single-center Investigator-Initiated Trial (IIT) designed to evaluate the safety, pharmacokinetic profile, and preliminary efficacy of CD19-BCMA CAR-T cells in subjects diagnosed with connective tissue diseases.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-26.
Status change: Recruiting → Withdrawn 2026-05-26
Trial Details
NCT Number NCT07152223
Lead Sponsor Guangzhou Bio-gene Technology Co., Ltd
Conditions Connective Tissue Diseases
Start Date 2025-08-07
Primary Completion 2026-03-02 (estimated)
Study Completion 2026-03-02 (estimated)
Updated on ClinicalTrials.gov 2026-05-28